Loading organizations...
§ Private Profile · Winterthur, Zurich, Switzerland
Medtech startup developing in-situ UVC light disinfection devices for hospitals, preventing catheter-related infections.
Founded in 2021 by Henry Twerenbold, Eashan Saikia, RS Lima, and Alejandro Ojeda, Aseptuva is a Swiss medical technology company developing adaptors that utilize targeted UVC light for the continuous disinfection of catheter entry sites without chemicals. The startup targets bloodstream infections in intensive care units, aiming to prevent infections and reduce severe patient complications alongside treatment costs that can reach $45,000 per episode. Operating with a team of seven employees, the organization has reached the functional prototype stage, filed patents, and successfully completed preclinical studies. Aseptuva has secured funding comprising 1,3 million CHF in equity and 1,5 million CHF in nondilutive grants from recognizable backers like Valuemaker AG, Fortyone AG, Venture Kick, and Innosuisse. Headquartered in Winterthur, the enterprise was recently selected as a Venture Leader Medtech and continues advancing its devices for clinical validation.
Aseptuva has raised $730K across 2 funding rounds.
Aseptuva has raised $730K in total across 2 funding rounds.
Aseptuva has raised $730K across 2 funding rounds. Most recently, it raised $210K Other Equity in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 3, 2023 | $210K Venture Round | — | — | Announced |
| Aug 30, 2022 | $520K Pre Seed | Fortyone, Valuemaker | — | Announced |
Aseptuva has raised $730K in total across 2 funding rounds.
Aseptuva's investors include Fortyone, Valuemaker.